Paragon launches biopharmaceutical companies that embody our core value of patient-centric, biomedical innovation.
LAUNCHED BY PARAGON
Castle Creek Biosciences
Evozyne is a world-leading company that creates novel proteins with exceptionally advanced functionality based on data-driven molecular engineering. Evozyne is working with some of the largest and most innovative companies to solve their pressing challenges. For more information, please visit www.evozyne.com.
Harmony Biosciences is a U.S. commercial-stage pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs. Harmony's mission is to positively impact the lives of those living with rare diseases who are so often underserved. For more information, please visit www.harmonybiosciences.com.
Qlarity Imaging improves patient care by building AI-driven products that provide clinical insights which radiologists do not have access to today. One of Qlarity’s initial products, QuantX Advanced, is the first FDA-cleared, computer-aided breast cancer diagnosis software for radiology. For more information, please visit www.qlarityimaging.com.
Skyline Biosciences is developing first in-kind oncology therapies to treat premalignant conditions with unmet medical need. Skyline’s mission is to alleviate potentially life-threatening conditions and to improve the quality of life for the patients it serves. For more information, please visit www.skylinebiosciences.com.